QLC1101 + docetaxel

QLC1101 + docetaxel is a **combination therapy** under clinical investigation for the treatment of patients with advanced solid tumors harboring a KRAS G12D mutation. QLC1101 is a selective, reversible small molecule inhibitor that specifically targets and binds to the KRAS G12D mutant protein, blocking downstream oncogenic signaling and inhibiting tumor cell growth. Docetaxel is a well-established antineoplastic agent classified as a taxane; it promotes microtubule stabilization, thereby inhibiting cell division and inducing apoptosis in rapidly proliferating tumor cells. The combination is being evaluated in Phase Ib/II clinical trials to assess safety, tolerability, and efficacy, and is sponsored by Qilu Pharmaceutical. The principal investigational focus is on advanced solid tumors with KRAS G12D mutations, including but not limited to non-small cell lung cancer, colorectal cancer, and pancreatic cancer[1][4][5][10].